Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.42 |
| ▸ | HTR1B | P28222 | 9/20 | 0.42 |
| ▸ | HTR1D | P28221 | 8/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11820703 | 0.95 | HTR1A (0.44) | HTR1AHTR1BHTR1DSIGMAR1KDM4E | |
| SCHEMBL1795521 | 0.93 | HTR1A (0.38) | HTR1AHTR1BHTR1DPIM1PIM2 | |
| SCHEMBL1796385 | 0.91 | TAAR1 (0.45) | HTR1AHTR1BHTR1DPDK2KDM4E | |
| SCHEMBL1795750 | 0.90 | KDM4E (0.49) | HTR1AHTR1BHTR1DPIM1PIM2 | |
| SCHEMBL1797544 | 0.85 | HTR1B (0.39) | HTR1AHTR1BHTR1DPIM1PDK2 | |
| SCHEMBL1795570 | 0.84 | TAAR1 (0.40) | HTR1AHTR1BHTR1DKDM4EMAPT | |
| SCHEMBL15805864 | 0.82 | PIM1 (0.43) | HTR1BPIM1PIM2MAPK1 | |
| SCHEMBL1799775 | 0.81 | KDM4E (0.50) | HTR1AHTR1BHTR1DSIGMAR1KDM4E | |
| SCHEMBL1793723 | 0.80 | ALDH2 (0.41) | HTR1AHTR1BHTR1DPIM1PIM2 | |
| SCHEMBL13502295 | 0.79 | MTNR1A (0.47) | HTR1AHTR1BKDM4ETP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | claimed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | claimed |
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | HTR1A 32/4885HTR1B 34/4885HTR1D 76/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | HTR1A 39/4885HTR1B 42/4885HTR1D 80/4885 |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRM1, CHRM3, CHRNA1 | HTR1A 37/4885HTR1B 39/4885HTR1D 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.